Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

PMSF [329-98-6]

Imprimir

Referência NB-64-00950-100mg

Tamanho : 100mg

Marca : Neo Biotech

Solicitar mais informações

Remove All

PMSF

(Synonyms: Phenylmethylsulfonyl fluoride, Benzylsulfonyl fluoride) Copy Product Info

Synonyms: Phenylmethylsulfonyl fluoride, Benzylsulfonyl fluoride

Catalog No. T0789 Copy Product Info

Purity: 99.88%

PMSF (Phenylmethylsulfonyl fluoride) is an irreversible inhibitor of serine/cysteine protease and is often used in the preparation of cell lysates.

Cas No. 329-98-6

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.88%

Color:White

Product Introduction

Bioactivity

Description	PMSF (Phenylmethylsulfonyl fluoride) is an irreversible inhibitor of serine/cysteine protease and is often used in the preparation of cell lysates.
Targets & IC50	hypothermia (mouse):224 mg/kg (ED50), Neutrophil:95 μM, Neutrophil:130.9 μM, Neutrophil:22.8 μg/mL, Remain immobile (mouse):206 mg/kg (ED50), antinociception (mouse):86 mg/kg (ED50)
In vitro	Treatment with PMSF (intraperitoneal injection) in mice elicits cannabinoid-like effects, providing analgesia (ED50: 86 mg/kg), hypothermia (ED50: 224 mg/kg), and catalepsy (ED50: 206 mg/kg). When administered to Sprague-Dawley rats, PMSF induces a dose-dependent analgesic effect and significantly potentiates the analgesic effect of β-endorphin in vivo. By inhibiting fatty acid amide hydrolase (FAAH) activity, PMSF suppresses typical cannabinoid or Δ(9)-tetrahydrocannabinol-like effects in ICR mice. Pretreatment with 30 mg/kg PMSF before the injection of [3H]-labeled cannabinoids results in a notable increase in brain cannabinoid levels after 5 minutes compared to [3H]-THC. PMSF pretreatment at 30 mg/kg enhances the cannabinoid-induced effects on the tail-flick response (analgesic effect), locomotion, and spontaneous activity by 5, 8, and 10-fold respectively. Administering PMSF 12 hours before paraoxon (PSP) protects hens from delayed neurotoxicity, whereas administration 4 hours later exacerbates the neurotoxic effects. PMSF pretreatment also prevents organophosphate-induced delayed neuropathy in hens and inhibits neuropathilament degeneration induced by tri-ortho-tolyl phosphate.
In vivo	METHODS: To study the analgesic effect of PMSF, PMSF was intraperitoneally injected into mice. RESULTS: Mice exhibited cannabinoid effects: including analgesia, hypothermia and immobility, with ED50 values of 86, 224 and 206 mg/kg, respectively.
Synonyms	Phenylmethylsulfonyl fluoride, Benzylsulfonyl fluoride

Chemical Properties

Molecular Weight	174.19
Formula	C₇H₇FO₂S
Cas No.	329-98-6
Smiles	FS(=O)(=O)Cc1ccccc1
Relative Density.	0.797g/mLat 20°C

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 17.4 mg/mL (99.89 mM), Sonication is recommended.

DMSO: 257.5 mg/mL (1478.27 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (28.7 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	5.7409 mL	28.7043 mL	57.4086 mL	287.0429 mL
5 mM	1.1482 mL	5.7409 mL	11.4817 mL	57.4086 mL
10 mM	0.5741 mL	2.8704 mL	5.7409 mL	28.7043 mL
20 mM	0.2870 mL	1.4352 mL	2.8704 mL	14.3521 mL
50 mM	0.1148 mL	0.5741 mL	1.1482 mL	5.7409 mL

DMSO

	1mg	5mg	10mg	50mg
100 mM	0.0574 mL	0.2870 mL	0.5741 mL	2.8704 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

SerineProteaseSerine ProteasePMSFPhenylmethylsulfonyl FluorideInhibitorinhibitCysteineProteaseCysteine proteaseCathepsinBenzylsulfonyl Fluoride

Related Tags: PMSF chemical structure | PMSF in vivo | PMSF in vitro | PMSF formula | PMSF molecular weight